Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up
This article was originally published in PharmAsia News
Executive Summary
The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.